host
respons
foreign
substanc
often
well
orchestr
seri
event
design
protect
individu
harm
modern
techniqu
help
us
elucid
pathway
compon
host
respons
immun
system
compon
mainstay
protect
infect
malign
inflamm
often
unpleas
side
effect
immun
system
contain
erad
microb
foreign
tissu
specif
arm
immun
system
use
marker
favor
presenc
infect
humor
antibodi
respons
invad
microb
exampl
antibodi
produc
protect
effect
part
immuneinflammatori
system
respons
erad
infect
antibodi
may
effect
role
howev
abil
recogn
uniqu
specif
structur
microb
serv
beacon
microb
recent
present
present
distant
past
substanc
antibiot
rapidli
kill
microb
may
modifi
immun
respons
remov
infecti
drive
forc
fullscal
respons
clinic
medicin
veterinari
medicin
measur
immun
respons
help
diagnostician
decid
infect
present
recent
situat
intent
provid
treatment
piec
puzzl
forens
scientist
may
exploit
part
immun
respons
discov
like
victim
attack
might
respons
chapter
discuss
basic
host
immun
respons
util
microbi
forens
sens
exampl
provid
sens
inform
achiev
like
provid
clue
high
degre
certainti
respons
encount
new
microb
immun
system
first
start
activ
antibodi
system
usual
cell
known
macrophag
engulf
microb
present
part
microb
helper
cell
lymphocyt
direct
lymphocyt
known
b
cell
produc
antibodi
particular
microb
even
specif
part
present
usual
take
least
day
microbespecif
antibodi
found
antibodi
specif
form
protein
known
immunoglobulin
ig
igm
igg
iga
princip
class
immunoglobulin
relev
chapter
discuss
detail
individu
unfortun
allergi
problem
due
ige
allergen
ragwe
peanut
cat
dander
case
ige
molecul
sit
surfac
cell
releas
histamin
offend
allergen
bridg
microbi
forens
host
factor
two
molecul
infect
immunoglobulin
usual
appear
order
igm
igg
iga
b
cell
first
begin
produc
igm
b
cell
undergo
irrevers
switch
produc
igg
later
popul
cell
undergo
switch
becom
igasecret
type
b
cell
immunoglobulin
persist
vari
time
exampl
halflif
particular
igm
antibodi
day
igg
long
day
tabl
similar
live
microb
vaccin
also
provok
antibodi
respons
vaccin
compos
live
attenu
microb
whole
nonprolifer
microb
antigen
part
microb
regardless
intent
vaccin
produc
protect
often
protect
antibodi
although
halflif
individu
igg
molecul
less
month
popul
antibodi
igg
isotyp
form
may
persist
life
memori
b
cell
sustain
antibodi
retain
abil
quickli
gener
appropri
antibodi
challeng
immun
system
encount
anoth
infect
subject
revaccin
booster
result
acceler
product
particular
antibodi
increas
level
circul
blood
figur
illustr
perhap
discern
pattern
antibodi
respons
forens
valu
appear
igm
first
follow
bcell
switch
longer
last
igg
earli
phase
exposur
igm
seen
first
time
goe
igg
seen
predomin
igm
longer
found
illustr
figur
antibodi
respons
particular
agent
may
direct
differ
antigen
differ
time
earli
later
initi
exposur
respons
may
involv
igm
earli
stage
igg
later
late
diseas
recoveri
igg
particular
antigen
may
seen
classic
exampl
human
antibodi
respons
epstein
barr
viru
ebv
ebv
viru
known
caus
mononucleosi
acut
earli
diseas
common
find
high
level
antibodi
igm
isotyp
viral
earli
antigen
ea
viral
capsid
antigen
vca
rare
find
igg
antibodi
vca
epstein
barr
nuclear
acid
ebna
anyth
low
titer
patient
recov
first
infect
ebv
rare
find
anyth
low
level
igm
ea
vca
igg
vca
higher
increas
level
common
antibodi
ebna
often
low
stage
clinic
recoveri
sever
month
later
igm
ea
vca
stay
low
level
wherea
igg
vca
ebna
remain
high
level
often
year
tabl
illustr
pattern
stage
immun
respons
ebv
particular
antigen
figur
graphic
display
clinician
epidemiologist
provid
framework
determin
infecti
process
patient
may
tabl
control
experi
normal
clinic
event
illustr
happen
immun
system
see
infecti
agent
vaccin
represent
control
experi
may
laboratori
anim
patient
receiv
booster
vaccin
uncontrol
normal
clinic
event
occur
patient
expos
infecti
agent
whatev
reason
consid
gener
antigen
exposur
first
time
immun
system
see
antigen
x
agx
respond
shown
figur
first
antibodi
agx
bare
discern
level
rise
later
fall
plateau
mix
infecti
exposur
occur
agx
new
agi
anoth
microb
immun
system
would
quickli
mount
brisk
high
level
ab
agx
cours
ab
agi
would
slow
delay
first
exposur
agx
agx
phenomenon
term
immunolog
memori
amnest
respons
use
symptom
sign
exposur
either
x
similar
case
earli
flulik
symptom
pulmonari
anthrax
influenza
viru
anoth
exampl
common
us
repetit
exposur
differ
strain
flu
virus
illustr
tabl
person
infect
first
time
one
strain
influenza
viru
make
respons
antigen
theoret
exampl
ag
three
year
later
individu
expos
partial
similar
influenza
viru
respond
preferenti
antigen
also
present
origin
influenza
viru
person
also
make
smaller
initi
antibodi
respons
new
antigen
share
first
viru
initi
respons
minim
comparison
ten
year
later
new
flu
season
exposur
third
strain
influenza
brisk
respons
would
antigen
previous
recogn
immun
system
scientif
basi
give
flu
vaccin
contain
varieti
possibl
antigen
common
multipl
strain
flu
viru
rapid
protect
antibodi
respons
occur
knowledg
humor
respons
infect
biothreat
microb
limit
compar
knowledg
kinet
time
respons
common
human
infect
nevertheless
appropri
context
suffici
background
inform
detect
antibodi
particular
microb
antigen
import
valu
microbi
forens
inform
may
critic
prob
valu
guid
investig
lead
absenc
specif
antibodi
respons
may
also
equal
valu
particular
investig
certainli
import
increas
context
knowledg
organ
may
involv
exposur
like
occur
rout
exposur
symptom
sign
manifest
host
hard
data
point
detect
antigen
detect
microbi
dna
rna
inform
mani
host
peopl
anim
infect
geograph
region
normal
infect
rate
background
incid
antibodi
titer
due
organ
question
relat
organ
also
import
anthrax
letter
attack
rais
multipl
question
everi
person
infect
possibl
expos
vaccin
treat
question
includ
person
infect
skin
could
produc
cutan
anthrax
inhal
spore
would
produc
pulmonari
system
anthrax
infect
ingest
spore
would
produc
initi
gastrointestin
infect
among
worri
well
consid
situat
close
associ
come
symptom
compat
anthrax
infect
receiv
powdercontain
letter
disprov
anthrax
great
worri
ensu
learn
limit
textbook
medicin
appli
yet
use
inform
use
present
design
futur
studi
sever
case
document
exposur
enough
time
patient
develop
antibodi
specif
anthrax
antigen
least
probe
igg
serial
serum
sampl
obtain
novemb
well
potenti
work
place
exposur
first
week
octob
test
igg
antibodi
protect
antigen
pa
compon
anthrax
toxin
enzymelink
immunosorb
assay
elisa
sampl
nonreact
serial
test
serum
igg
antibodi
pa
toxin
anthrax
perform
workplaceexpos
person
one
test
neg
specimen
collect
octob
instruct
look
posit
antibodi
case
context
durat
individu
symptom
develop
posit
test
none
symptom
detail
individu
uniqu
rais
suspicion
particular
diagnosi
man
case
develop
fatigu
septemb
newspap
mailroom
clerk
deliv
mail
first
patient
case
septemb
develop
nonproduct
cough
intermitt
fever
runni
nose
conjunct
symptom
worsen
octob
hospit
addit
short
breath
exert
sweat
mild
abdomin
pain
vomit
episod
confus
temperatur
elev
heart
rate
rapid
respiratori
rate
slightli
fast
blood
pressur
mm
hg
bilater
conjunctiv
inject
bilater
pulmonari
rhonchi
time
neurolog
exam
normal
skin
lesion
observ
laboratori
abnorm
low
albumin
elev
liver
transaminas
borderlin
low
serum
sodium
increas
creatinin
low
oxygen
content
blood
blood
cultur
neg
hospit
day
antibiot
start
chest
xray
show
leftsid
pneumonia
small
left
pleural
effus
classic
mediastin
widen
patient
initi
given
intraven
azithromycin
cefotaxim
ciprofloxacin
subsequ
ad
nasal
swab
obtain
octob
grew
bacillu
anthraci
cultur
comput
tomographi
ct
chest
show
bilater
effus
multilobar
pulmonari
consolid
still
signific
mediastin
lymphadenopathi
pleural
fluid
aspir
posit
b
anthraci
dna
pcr
bacteri
cultur
bronchial
wash
pleural
fluid
neg
transbronchi
biopsi
show
b
anthraci
capsul
cellwal
antigen
immunohistochem
stain
hospit
white
blood
count
rose
fluid
second
thoracentesi
posit
b
anthraci
dna
pcr
pleural
fluid
cell
pleural
biopsi
tissu
show
b
anthraci
capsul
cellwal
antigen
immunohistochem
stain
serial
serum
sampl
demonstr
greater
fourfold
rise
serum
igg
antibodi
pa
compon
anthrax
toxin
elisa
assay
patient
abl
leav
hospit
octob
oral
ciprofloxacin
tabl
illustr
clinic
bioforens
approach
context
analyz
patient
like
common
situat
biocrim
suspect
affect
individu
first
set
question
revolv
around
whether
person
sick
patient
indic
well
laboratori
evid
suggest
infect
second
set
question
address
whether
specif
object
laboratori
evid
particular
infect
case
point
direct
cultur
may
neg
differ
time
differ
fluid
tissu
may
influenc
earli
administr
antibiot
howev
remnant
infect
even
dead
util
serolog
analysi
peopl
expos
anthrax
organ
found
probe
antigen
dna
patient
manifest
classic
principl
infecti
diseas
rise
antibodi
titer
time
case
igg
particular
antigen
anthrax
toxin
antibodi
respons
may
detect
earlier
igm
toxin
antigen
anthrax
sought
case
also
point
util
integr
presenc
antibodi
indic
anthrax
infect
take
greatest
signific
clinic
symptom
sign
infect
possibl
expos
individu
earli
administr
antibiot
prevent
posit
cultur
organ
question
first
pulmonari
anthrax
case
associ
anthrax
letter
attack
three
patient
cultur
growth
b
anthraci
clinic
sampl
cultur
attempt
initi
antibiot
therapi
diagnosi
made
basi
histori
exposur
conjunct
compat
symptom
sign
diseas
object
laboratori
find
b
anthraci
identifi
pleural
fluid
pleural
biopsi
transbronchi
biopsi
specimen
reactiv
b
anthracisspecif
cell
wall
capsular
antibodi
dna
pcr
pleural
fluid
blood
import
understand
limit
assay
use
iggbas
elisa
anthrax
toxin
protect
antigen
pa
compon
illustr
import
understand
limit
assay
elisa
assay
develop
us
armi
medic
research
institut
infecti
diseas
usamriid
put
oper
optim
cdc
function
sensit
specif
detect
antibodi
respons
b
anthraci
infect
major
limit
restrict
one
antigen
igg
therefor
neg
result
time
earli
exposur
may
effect
yield
falseneg
result
identifi
gap
knowledg
applic
fill
develop
igm
assay
perhap
one
enhanc
probe
b
anthraci
antigen
epitop
yet
discov
assay
may
use
present
form
screen
asymptomat
peopl
possibl
exposur
studi
dewan
et
al
give
sens
provid
contemporari
background
databas
group
individu
may
expos
b
anthraci
evalu
postal
worker
begin
octob
employe
other
washington
dc
postal
facil
went
dc
gener
hospit
antibiot
addit
begun
octob
serum
sampl
obtain
individu
neg
specif
igg
antibodi
pa
igg
includ
three
particip
report
remot
histori
anthrax
vaccin
limit
data
fact
antibiot
begun
serum
test
baselin
serum
sampl
avail
test
also
time
period
exposur
sampl
short
among
individu
posit
nasal
swab
capitol
exposur
receiv
antibiot
immedi
none
posit
cultur
nasal
swab
repeat
day
later
none
posit
serum
igg
pa
antigen
day
exposur
emphas
limit
interpret
test
someon
earli
antibiot
treatment
rais
forens
consider
even
easili
dissemin
strain
antibodi
respons
may
abort
modifi
antibiot
earli
erad
furthermor
antibiot
taken
prior
exposur
would
like
effect
prevent
laboratori
clinic
sign
infect
exposur
detect
dna
antigen
organ
person
bodi
cloth
possess
would
rais
red
flag
rout
infect
equal
import
interpret
result
limit
assay
use
exampl
cutan
anthrax
paraguay
illustr
well
notion
search
antigen
marker
exposur
analysi
outbreak
least
case
cutan
anthrax
develop
touch
raw
meat
sick
cow
perform
serum
case
coloni
two
noncoloni
control
week
outbreak
blot
antibodi
pa
lethal
util
serolog
analysi
peopl
expos
anthrax
factor
compon
anthrax
toxin
elisa
use
probe
antibodi
polydglutam
acid
capsul
case
posit
pa
screen
sensit
none
control
posit
specif
six
case
antibodi
lethal
factor
control
neg
probe
antibodi
capsul
posit
posit
two
control
studi
demonstr
need
consid
antigen
principl
discuss
highlight
recent
report
sar
coronaviru
diseas
also
evok
concern
possibl
terrorist
origin
onset
report
morbid
mortal
weekli
report
mmwr
preval
igg
antibodi
sarsassoci
coronaviru
anim
trader
discuss
need
valid
interpret
test
appropri
populationsth
igg
test
discuss
inabl
date
time
infect
possibl
reactiv
near
neighbor
might
unknown
prome
bulletin
dr
berger
look
data
differ
angl
report
week
studi
mmwr
indic
anim
contact
may
inde
promot
infect
howev
strike
find
seem
elud
author
percent
percent
individu
healthi
control
group
adult
also
found
seroposit
popul
guangdong
provinc
million
million
adult
age
assum
seroposit
rate
among
control
repres
provinc
whole
adult
guangdong
time
infect
sar
viru
figur
total
number
sar
patient
report
worldwid
date
good
illustr
need
question
methodolog
acquisit
data
accept
applic
formula
analys
yersinia
pesti
caus
plagu
zoonot
infect
occur
us
regular
anim
reservoir
contrast
case
smallpox
would
rais
immedi
red
flag
bioterrorist
event
case
need
approach
epidemiolog
standpoint
first
determin
whether
expect
case
whether
fact
point
deliber
introduct
organ
group
peopl
individu
analyt
techniqu
could
includ
genom
analysi
isol
organ
immunolog
respons
host
consider
anim
reservoir
elisa
assay
compar
test
detect
plagu
antibodi
microbi
forens
host
factor
antigen
multimamm
mice
mastomi
coucha
natalensi
experiment
infect
sacrif
daili
interv
igg
elisa
equival
sensit
passiv
hemagglutin
sensit
igm
elisa
complement
fixat
antibodi
detect
day
infect
use
four
test
igm
elisa
titer
fell
undetect
level
week
plagu
fraction
antigen
detect
bacterem
sera
coucha
natalensi
show
principl
igm
versu
igg
pathogen
work
tempor
situat
infect
earli
versu
late
past
also
show
inform
combin
antigen
detect
engend
confid
result
melioidosi
caus
burkholderia
pseudomallei
also
exampl
key
clinic
sign
laboratori
featur
rais
possibl
infect
relat
studi
observ
present
illustr
tempor
issu
host
respons
need
interpret
result
assay
appropri
clinic
geograph
set
whether
acut
infect
persist
one
past
infect
determin
look
sever
host
respons
often
simpl
indic
infect
erythrocyt
sediment
rate
creactiv
protein
crp
creat
clinic
suspicion
begin
probe
specif
infect
studi
patient
clinic
melioidosi
cultureposit
cultureneg
rel
unev
diseas
cours
initi
elev
serum
crp
decreas
antibiot
therapi
return
normal
diseas
resolv
anoth
seri
patient
igm
igg
measur
elisa
sera
septicem
case
sera
case
local
melioidosi
sixtyf
sera
cultureneg
case
seroneg
endem
infect
suspect
melioidosi
also
examin
control
includ
nonmelioidosi
case
highexposurerisk
case
healthi
individu
iggelisa
sensit
specif
sera
case
septicem
local
infect
sera
clinic
suspect
melioidosi
case
posit
igg
antibodi
sensit
specif
igm
elisa
respect
geometr
index
igm
antibodi
sera
melioidosi
case
significantli
higher
melioidosi
case
compar
nonmelioidosi
diseas
control
anoth
studi
author
use
rapid
test
also
show
igg
igm
clinic
util
anoth
studi
intent
evalu
util
igg
assay
compar
assay
illustr
clinic
tempor
context
must
integr
interpret
also
illustr
room
improv
test
best
analysi
result
understand
condit
endem
area
util
sampl
control
area
test
evalu
actual
clinic
set
area
endem
melioidosi
specif
specif
igg
specif
igm
significantli
better
indirect
hemagglutin
test
sensit
specif
igg
assay
higher
iha
test
specif
igm
test
specif
igg
found
septicem
case
local
form
specif
igg
test
also
better
specif
igm
test
iha
test
identifi
acut
melioidosi
case
first
five
day
admiss
igg
antibodi
b
pseudomallei
antigen
remain
high
longer
year
recov
diseasefre
patient
diseas
may
incub
day
year
acut
case
may
well
pick
igm
versu
igg
matter
day
infect
although
endem
southeast
asia
use
biothreat
agent
differ
environ
etiolog
may
recogn
immedi
import
understand
endem
area
factor
well
host
microb
illustr
anoth
zoonot
exampl
rift
valley
fever
viru
rvfv
transmit
via
aerosol
one
studi
intent
look
improv
test
show
util
igm
determin
earli
exposur
rvfv
two
elisa
igm
test
detect
specif
igm
antibodi
rvfv
first
week
vaccin
three
inactiv
vaccin
dose
given
day
elisa
serum
igm
day
neg
lower
rang
signific
day
strongli
posit
day
wane
later
neg
plaqu
reduct
neutral
test
neg
day
becam
posit
later
sampl
similar
exampl
shown
data
suggest
three
dose
rvfv
vaccin
induc
prolong
primari
antibodi
respons
author
studi
conclud
elisa
igm
could
becom
import
tool
earli
diagnosi
acut
human
infect
good
correl
neutral
test
elisa
igg
would
indic
later
infect
taken
togeth
exampl
illustr
ideal
test
clinic
forens
use
would
incorpor
endem
area
control
histor
contextu
inform
knowledg
rout
exposur
background
incid
kinet
transmiss
scenario
must
take
account
multipl
factor
limit
analyt
process
appli
often
consid
understand
element
posit
neg
predict
valu
assay
within
popul
test
one
extrem
situat
occur
onset
human
immun
defici
hiv
us
first
case
therefor
precis
highli
sensit
specif
test
excel
posit
neg
predict
valu
exist
combin
test
use
would
like
yield
posit
result
area
littl
diseas
onset
kansa
exampl
posit
test
today
methodolog
serum
sampl
kansa
would
consid
probabl
falseposit
warrant
investig
howev
sampl
test
begin
hiv
test
could
posit
person
adult
tcell
leukemia
caus
human
tcell
leukemia
origin
test
becam
known
acquir
immunodefici
syndrom
aid
involv
whole
viral
lysat
sera
crossreact
suspicion
contrari
would
rais
knowledg
differ
present
infect
exampl
actual
use
laboratori
immort
cell
patient
actual
increas
tcell
count
natur
leukemia
instead
decreas
hiv
infect
laboratori
indic
hypercalcemia
would
rais
leukemia
consider
interpret
posit
clinic
test
must
take
account
health
statu
person
test
import
practic
medicin
relev
extend
forens
analysi
follow
situat
illustr
concept
individu
syphili
bacteri
spirochet
infect
typic
posit
fta
fluoresc
treponem
antibodi
test
year
howev
infect
would
posit
vener
diseas
research
laboratori
vdrl
test
revert
neg
success
antibiot
therapi
notabl
except
relat
crossreact
epitop
autoimmun
diseas
readili
distinguish
histori
clinic
inform
similarli
individu
infect
tuberculosi
posit
skin
test
mantoux
wherea
uninfect
healthi
person
neg
certain
instanc
sick
person
cellmedi
immun
defici
anerg
hesh
neg
multipl
skin
test
includ
common
antigen
candida
key
differ
wide
differ
healthi
person
test
ill
individu
subject
test
test
may
also
discrimin
time
infect
acut
chronic
limit
may
lead
differ
interpret
unless
one
familiar
limit
exampl
occur
bacteri
infect
borrelia
burgdorferi
caus
lyme
diseas
dattwyl
group
show
antibiot
could
abrog
antibodi
respons
elisa
result
neg
patient
known
diseas
treat
earli
anoth
group
show
earli
case
reactiv
uniqu
antigen
ospa
also
neg
serolog
assay
despit
demonstr
tcell
respons
group
opportun
possibl
scenario
bioterror
attack
analyz
sera
found
antibodi
b
burgdorferi
threshold
convent
assay
detect
bound
form
immun
complex
anthrax
use
exampl
investigatori
lead
gener
consid
scenario
toto
elderli
ladi
die
connecticut
anthrax
clearli
occup
exposur
known
contact
anyon
anthrax
possibl
receiv
contamin
mail
howev
case
occur
index
case
context
mail
attack
would
reason
question
travel
histori
work
receiv
use
product
endem
area
anthrax
similarli
vietnames
woman
die
new
york
citi
would
also
question
investig
would
use
search
direct
indirect
evid
anthrax
physic
examin
contact
close
neighbor
inspect
cultur
workplac
apart
apart
complex
especi
contigu
neighbor
import
presenc
anthrax
cowork
friend
neighbor
contact
could
blood
sampl
analyz
antibodi
anthrax
antigen
sampl
could
frozen
one
posit
would
avail
comparison
studi
futur
minimum
type
studi
could
serv
futur
control
data
geograph
region
although
hypothet
sever
result
could
occur
analyz
separ
first
exampl
close
contact
posit
igm
one
b
anthraci
antigen
eg
pa
would
suggest
person
recent
exposur
noth
els
treat
individu
could
conceiv
one
knowingli
unknowingli
pass
spore
patient
given
octob
onset
ill
late
mail
sequenc
would
less
like
individu
perpetr
rather
recent
victim
howev
person
iggposit
assay
sever
possibl
perhap
person
past
exposur
endem
region
subclin
treat
ill
eg
haiti
anthrax
known
charcoal
diseas
person
could
vaccin
bona
fide
reason
research
receiv
occup
protect
person
could
obtain
vaccin
origin
legitim
illeg
purpos
nevertheless
vaccin
anim
vaccin
may
obtain
without
strict
record
keep
person
could
load
mail
rel
impun
protect
antibodi
gener
vaccin
situat
requir
intellig
inform
regard
access
abil
motiv
howev
igg
find
could
point
investig
toward
individu
wherea
igm
find
justifi
critic
therapi
come
direct
inform
point
particular
individu
investig
could
extend
ingest
antibiot
question
would
rais
microbi
forens
host
factor
regard
access
antibiot
recent
ingest
halflif
antibiot
halflif
metabolit
antibiot
bodi
fluid
tissu
residu
found
illustr
data
earlier
section
someon
antibiot
system
could
protect
exposur
sensit
microb
person
would
antibodyneg
like
antigenand
microbi
dnarnaneg
sinc
infect
would
erad
organ
could
prolifer
signific
quantiti
similar
strategi
employ
examin
suspici
possibl
accident
transmiss
infect
illustr
recent
seri
aviant
flu
tool
determin
person
person
spread
transmiss
mode
includ
viral
cultur
serolog
analysi
immunohistochem
assay
reversetranscriptasepolymerasechainreact
rtpcr
analysi
genet
sequenc
like
futur
understand
immun
system
evolv
technolog
microarray
bring
new
analyt
power
scene
meantim
make
good
use
proven
principl
forens
purpos
